AR071380A1 - Compuestos que tienen actividad antagonistica del receptor y5 de npy y composiciones farmaceuticas que los contienen - Google Patents
Compuestos que tienen actividad antagonistica del receptor y5 de npy y composiciones farmaceuticas que los contienenInfo
- Publication number
- AR071380A1 AR071380A1 ARP090101383A ARP090101383A AR071380A1 AR 071380 A1 AR071380 A1 AR 071380A1 AR P090101383 A ARP090101383 A AR P090101383A AR P090101383 A ARP090101383 A AR P090101383A AR 071380 A1 AR071380 A1 AR 071380A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- optionally
- compounds
- alkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 102000028582 Neuropeptide Y5 receptor Human genes 0.000 title 1
- 108010046593 Neuropeptide Y5 receptor Proteins 0.000 title 1
- 230000003042 antagnostic effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000000304 alkynyl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 abstract 1
- 125000005090 alkenylcarbonyl group Chemical group 0.000 abstract 1
- 125000003302 alkenyloxy group Chemical group 0.000 abstract 1
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 abstract 1
- 125000005137 alkenylsulfonyl group Chemical group 0.000 abstract 1
- 125000005108 alkenylthio group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 125000005129 aryl carbonyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 abstract 1
- 125000005110 aryl thio group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 150000001540 azides Chemical group 0.000 abstract 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000004465 cycloalkenyloxy group Chemical group 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000005170 cycloalkyloxycarbonyl group Chemical group 0.000 abstract 1
- 125000005144 cycloalkylsulfonyl group Chemical group 0.000 abstract 1
- 125000005366 cycloalkylthio group Chemical group 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 abstract 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 abstract 1
- 125000005368 heteroarylthio group Chemical group 0.000 abstract 1
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000005945 imidazopyridyl group Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 abstract 1
- 125000001715 oxadiazolyl group Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- -1 sulfino, sulfo Chemical group 0.000 abstract 1
- 125000003396 thiol group Chemical class [H]S* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Pyrrole Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicacion 1: Un compuesto caracterizado porque tiene la formula (1) su sal o solvato farmacéuticamente aceptable, en donde R1 es alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, o alquinilo sustituido o no sustituido, R2 es hidrogeno o, alquilo sustituido o no sustituido, el anillo A es heterociclo aromático monociclico o bicíclico, R3 es arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, o heterociclilo sustituido o no sustituido, R4 es halogeno, ciano, nitro, nitroso, azida, oxo, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, cicloalquenilo sustituido o no sustituido, hidroxi, alcoxi sustituido o no sustituido, alqueniloxi sustituido o no sustituido, cicloalquiloxi sustituido o no sustituido, cicloalqueniloxi sustituido o no sustituido, ariloxi sustituido o no sustituido, heteroariloxi sustituido o no sustituido, heterocicliloxi sustituido o no sustituido, mercapto, alquiltio sustituido o no sustituido, alqueniltio sustituido o no sustituido, cicloalquiltio sustituido o no sustituido, cicloalqueniltio sustituido o no sustituido, ariltio sustituido o no sustituido, heteroariltio sustituido o no sustituido, heterocicliltio sustituido o no sustituido, carboxi, alcoxicarbonilo sustituido o no sustituido, alqueniloxicarbonilo sustituido o no sustituido, cicloalquiloxicarbonilo sustituido o no sustituido, cicloalqueniloxicarbonilo sustituido o no sustituido, ariloxicarbonilo sustituido o no sustituido, heteroariloxicarbonilo sustituido o no sustituido, heterocicliloxicarbonilo sustituido o no sustituido, carbamoil sustituido o no sustituido, formilo, alquilcarbonilo sustituido o no sustituido, alquenilcarbonilo sustituido o no sustituido, cicloalquilcarbonilo sustituido o no sustituido, cicloalquenilcarbonilo sustituido o no sustituido, arilcarbonilo sustituido o no sustituido, heteroarilcarbonilo sustituido o no sustituido, heterociclilcarbonilo sustituido o no sustituido, sulfino, sulfo, alquilsulfonilo sustituido o no sustituido, alquenilsulfonilo sustituido o no sustituido, cicloalquilsulfonilo sustituido o no sustituido, cicloalquenilsulfonilo sustituido o no sustituido, arilsulfonilo sustituido o no sustituido, heteroarilsulfonilo sustituido o no sustituido, heterociclilsulfonilo sustituido o no sustituido, sulfamoil sustituido o no sustituido, o amino sustituido o no sustituido, m es un numero entero entre 0 y 2, siempre que m sea 1 cuando el anillo A es imidazol, pirazol o piridina, n es un numero entero entre 0 y 5, R es halogeno, oxo, ciano, nitro, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, o alquinilo sustituido o no sustituido, p es un numero entero entre 0 y 2, y siempre que los compuestos en donde un grupo de la formula (2) es purinilo que opcionalmente tiene R3 y/o R4, imidazopiridilo que opcionalmente tiene R3 y/o R4, benzimidazolilo que opcionalmente tiene R3 y/o R4, los compuestos de formulas (3) y los compuestos en donde un grupo de la formula (2) es oxadiazolilo que opcionalmente tiene R3 y/o R4, y R1 es metilo sustituido con fenilo opcionalmente sustituido, sean excluidos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008109778 | 2008-04-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR071380A1 true AR071380A1 (es) | 2010-06-16 |
Family
ID=41216829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090101383A AR071380A1 (es) | 2008-04-21 | 2009-04-20 | Compuestos que tienen actividad antagonistica del receptor y5 de npy y composiciones farmaceuticas que los contienen |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8129372B2 (es) |
| EP (1) | EP2280000A4 (es) |
| JP (1) | JP5392924B2 (es) |
| KR (1) | KR20100135266A (es) |
| CN (1) | CN102066322A (es) |
| AR (1) | AR071380A1 (es) |
| AU (1) | AU2009239051A1 (es) |
| BR (1) | BRPI0910761A2 (es) |
| CA (1) | CA2721576A1 (es) |
| CL (1) | CL2009000904A1 (es) |
| MX (1) | MX2010011289A (es) |
| RU (1) | RU2010147416A (es) |
| TW (1) | TW200946117A (es) |
| WO (1) | WO2009131096A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010101247A1 (ja) | 2009-03-05 | 2010-09-10 | 塩野義製薬株式会社 | Ｎｐｙ ｙ５受容体拮抗作用を有するシクロヘキサン誘導体 |
| JP5642661B2 (ja) | 2009-03-05 | 2014-12-17 | 塩野義製薬株式会社 | Ｎｐｙｙ５受容体拮抗作用を有するピペリジンおよびピロリジン誘導体 |
| WO2012070114A1 (ja) * | 2010-11-24 | 2012-05-31 | 塩野義製薬株式会社 | Ｎｐｙ ｙ５受容体拮抗作用を有するスルファミド誘導体 |
| JP5959075B2 (ja) * | 2011-05-31 | 2016-08-02 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | ネプリライシン阻害剤 |
| US20130158049A1 (en) * | 2011-12-20 | 2013-06-20 | Hoffmann-La Roche Inc. | 7-azaindole inhibitors of crac |
| US10118890B2 (en) | 2014-10-10 | 2018-11-06 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
| CN104356053B (zh) * | 2014-10-21 | 2017-01-18 | 天津大学 | 2‑(3‑卤素苯基)吡啶类衍生物的制备方法 |
| PE20210129A1 (es) * | 2017-12-18 | 2021-01-19 | Bristol Myers Squibb Co | Compuestos de 4-azaindol |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5602024A (en) | 1994-12-02 | 1997-02-11 | Synaptic Pharmaceutical Corporation | DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof |
| AU7692996A (en) | 1995-12-01 | 1997-06-27 | Ciba-Geigy Ag | Receptor antagonists |
| JPH1052940A (ja) | 1996-08-09 | 1998-02-24 | Kyocera Corp | 画像形成装置 |
| WO1998052940A1 (en) * | 1997-05-22 | 1998-11-26 | G.D. Searle And Co. | SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS |
| US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| EP0978516A4 (en) | 1998-01-29 | 2001-01-10 | Suntory Ltd | 1-CYCLOALKYL-1,8-NAPHTHYRIDINE-4-ONE DERIVATIVES HAVING PHOSPHODIESTERASE IV INHIBITING ACTIVITY |
| AU2298899A (en) | 1998-02-05 | 1999-08-23 | Takeda Chemical Industries Ltd. | Sulfonamide derivatives, process for producing the same and utilization thereof |
| CA2389681C (en) * | 1999-11-26 | 2010-11-02 | Shionogi & Co., Ltd. | Npy y5 antagonist |
| HK1045503A1 (zh) | 1999-12-16 | 2002-11-29 | Schering Corporation | 取代的咪唑神经肽yy5受体拮抗物 |
| WO2001054503A1 (en) | 2000-01-28 | 2001-08-02 | Akkadix Corporation | Methods for killing nematodes and nematode eggs using 4-phenoxy-6-aminopyrimidine derivatives |
| US6531478B2 (en) | 2000-02-24 | 2003-03-11 | Cheryl P. Kordik | Amino pyrazole derivatives useful for the treatment of obesity and other disorders |
| ES2242771T5 (es) * | 2000-09-15 | 2011-10-14 | Vertex Pharmaceuticals Incorporated | Compuestos de pirazol útiles como inhibidores de proteína quinasas. |
| CA2403307A1 (en) | 2001-10-23 | 2003-04-23 | Neurogen Corporation | Substituted 2-cyclohexyl-4-phenyl-1h-imidazole derivatives |
| AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| GB0226370D0 (en) | 2002-11-12 | 2002-12-18 | Novartis Ag | Organic compounds |
| CL2004000234A1 (es) | 2003-02-12 | 2005-04-15 | Biogen Idec Inc | Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid |
| DE10310226A1 (de) | 2003-03-08 | 2004-09-16 | Ina-Schaeffler Kg | Schlepphebel eines Ventiltriebs einer Brennkraftmaschine |
| CA2555409A1 (en) * | 2004-02-19 | 2005-09-01 | Banyu Pharmaceutical Co., Ltd. | Novel sulfone amide derivative |
| BRPI0512615A (pt) * | 2004-06-24 | 2008-03-25 | Shionogi & Co | compostos de sulfonamida |
| EP1804801A2 (en) * | 2004-10-15 | 2007-07-11 | Biogen Idec MA, Inc. | Methods of treating vascular injuries |
| US7723340B2 (en) | 2005-01-13 | 2010-05-25 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| TW200726767A (en) * | 2005-07-04 | 2007-07-16 | Astrazeneca Ab | Chemical compounds 2 |
| CA2635231C (en) | 2005-12-29 | 2014-07-15 | Abbott Laboratories | Protein kinase inhibitors |
| JP4528901B2 (ja) | 2006-04-28 | 2010-08-25 | 塩野義製薬株式会社 | Ｎｐｙｙ５受容体拮抗作用を有するアミン誘導体 |
| JP5207382B2 (ja) | 2006-08-30 | 2013-06-12 | 塩野義製薬株式会社 | ウレア誘導体 |
| EP2062878A4 (en) * | 2006-08-30 | 2010-09-08 | Shionogi & Co | HYDRAZINE AMIDE DERIVATIVE |
| SA08290668B1 (ar) | 2007-10-25 | 2012-02-12 | شيونوجي آند كو.، ليمتد | مشتقات أمين لها نشاط مضاد لمستقبل npy y5 واستخداماتها |
| US8227618B2 (en) | 2009-04-23 | 2012-07-24 | Shionogi & Co., Ltd. | Amine-derivatives having NPY Y5 receptor antagonistic activity and the uses thereof |
-
2009
- 2009-04-15 CL CL2009000904A patent/CL2009000904A1/es unknown
- 2009-04-20 US US12/936,693 patent/US8129372B2/en not_active Expired - Fee Related
- 2009-04-20 AU AU2009239051A patent/AU2009239051A1/en not_active Abandoned
- 2009-04-20 CA CA2721576A patent/CA2721576A1/en not_active Abandoned
- 2009-04-20 MX MX2010011289A patent/MX2010011289A/es active IP Right Grant
- 2009-04-20 CN CN2009801235209A patent/CN102066322A/zh active Pending
- 2009-04-20 WO PCT/JP2009/057856 patent/WO2009131096A1/ja not_active Ceased
- 2009-04-20 BR BRPI0910761-4A patent/BRPI0910761A2/pt not_active IP Right Cessation
- 2009-04-20 KR KR1020107023391A patent/KR20100135266A/ko not_active Withdrawn
- 2009-04-20 EP EP09733802A patent/EP2280000A4/en not_active Withdrawn
- 2009-04-20 JP JP2010509171A patent/JP5392924B2/ja not_active Expired - Fee Related
- 2009-04-20 RU RU2010147416/04A patent/RU2010147416A/ru not_active Application Discontinuation
- 2009-04-20 AR ARP090101383A patent/AR071380A1/es unknown
- 2009-04-21 TW TW098113111A patent/TW200946117A/zh unknown
-
2012
- 2012-01-20 US US13/354,881 patent/US8299066B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2721576A1 (en) | 2009-10-29 |
| US20120130070A1 (en) | 2012-05-24 |
| CN102066322A (zh) | 2011-05-18 |
| US8299066B2 (en) | 2012-10-30 |
| AU2009239051A1 (en) | 2009-10-29 |
| EP2280000A1 (en) | 2011-02-02 |
| US20110028468A1 (en) | 2011-02-03 |
| MX2010011289A (es) | 2010-11-10 |
| KR20100135266A (ko) | 2010-12-24 |
| BRPI0910761A2 (pt) | 2018-02-14 |
| CL2009000904A1 (es) | 2010-04-30 |
| TW200946117A (en) | 2009-11-16 |
| EP2280000A4 (en) | 2012-04-25 |
| JP5392924B2 (ja) | 2014-01-22 |
| JPWO2009131096A1 (ja) | 2011-08-18 |
| RU2010147416A (ru) | 2012-05-27 |
| US8129372B2 (en) | 2012-03-06 |
| WO2009131096A1 (ja) | 2009-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR071380A1 (es) | Compuestos que tienen actividad antagonistica del receptor y5 de npy y composiciones farmaceuticas que los contienen | |
| AR074238A1 (es) | Compuesto de n-{[(1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4,1.0]hept-4-il]metil}-2-heteroarilamina, su uso para la preparacion de un medicamento util para el tratamiento de una enfermedad que requiere un antagonista del receptor de orexina humano y composicion farmaceutica que lo comprende | |
| RU2010102529A (ru) | Способ борьбы с вредителями животных | |
| AR044519A1 (es) | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina | |
| AR066583A1 (es) | Derivados de 3,3-espiroindolinona | |
| ES2668775T3 (es) | Compuestos tetracíclicos | |
| AR066344A1 (es) | Compuesto de imidazol formulacion farmaceutica que lo comprende y uso del mismo para la manufactura de un medicamento | |
| AR074631A1 (es) | Compuesto de imidazol carboxamida, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar la depresion | |
| EA202190802A2 (ru) | Производные пиразолопиридина, обладающие эффектом агониста рецептора glp-1 | |
| ES2655091T3 (es) | Derivados del ácido pirrolidíncarboxílico como agonistas del receptor 43 acoplado a proteína G (GPR43), composición farmacéutica y métodos para su uso en el tratamiento de trastornos metabólicos | |
| AR080841A1 (es) | Derivados de isoxazolina sustituida; composiciones veterinarias que los comprenden y su uso en el tratamiento de parasitos en animales | |
| AR056964A1 (es) | Derivados de aminosulfonilo, composiciones farmaceuticas y sus usos | |
| AR064736A1 (es) | Agonistas de gpcr | |
| CO6260076A2 (es) | Derivados de uracilo o timina para el tratamiento de la hepatitis c | |
| CO6270288A2 (es) | Composicion fungicida que comprende cantidades significativamente efectivas de un derivadio de amida de acido carboxilico o su sal | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| RU2008152065A (ru) | Новое производное имидазола со спироциклической структурой в боковой цепи | |
| ES2478823T3 (es) | Derivados de iminopiridina y uso de los mismos | |
| AR066111A1 (es) | Compuesto triciclico de imidazol, su uso para preparar un medicamento, composicion farmaceutica que lo comprende y compuestos intermediarios en la sintesis de dicho compuesto | |
| AR076841A1 (es) | Derivados de triazol-sustituidos, procesos para su preparacion y metodos de uso en el control de plagas | |
| ES2662444T3 (es) | Derivado de piridina | |
| RU2012127701A (ru) | Производное оксадиазола, обладающее ингибирующей активностью в отношении эндотелиальной липазы | |
| MX2010006882A (es) | Derivado novedoso de catecol, composición farmaceutica que contiene el mismo, uso del derivado de catecol, y uso de la composición farmaceutica. | |
| AR085976A1 (es) | Inhibidores de la poli(adp-ribosa)polimerasa (parp) para el tratamiento de neuropatia periferica inducida por un quimioterapia (cipn) | |
| AR110128A2 (es) | Compuesto del grupo de las 3-(imidazoil)-pirazolo[3,4-b]piridinas, composición farmacéutica que lo comprende y método para preparar el mismo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |